Cooley M&A

OCTOBER 29, 2020

is the increased frequency at which SPAC IPOs are occurring. As reflected in Chart 1 , 102 SPAC IPOs have been announced this year as of September 18, 2020—almost double the number of SPAC IPOs in all of last year (and more than double the number of SPAC IPOs in 2018). SPAC vs. IPO. A distinct feature of SPAC 3.0

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

The TRADE

JULY 11, 2023

” The review consists of seven recommendations including the introduction of a Research Platform, which will provide a central facility for the promotion, sourcing and dissemination of research on publicly traded companies – potentially open to all, but in particular, for smaller cap companies.

Asset Management 40

Asset Management Investment Government Capital Market 40

Cooley M&A

JANUARY 25, 2023

2022 drivers and headwinds Choppy access to capital markets and financing to fund ongoing operations Many life sciences companies faced challenges raising money in the capital markets in 2022. Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 22, 2021

2020 was also a blockbuster year for special purpose acquisition company (SPAC) activity, as 247 SPAC IPOs raised more than $75 billion (a 525% increase compared to the amount raised by SPAC IPOs in 2019) [3]. Creative deal terms and financing arrangements were also attractive aspects of SPAC deals as compared to their IPO cousin.

M&A 40

M&A IPO Mergers and Acquisitions Business 40

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. 2021’s SPAC activity was most intense in the first quarter, with 298 SPAC IPOs priced and 97 deSPAC transactions announced in the first quarter alone.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Convergence of tech and healthcare drives digital health deals As discussed in our 2022 Life Sciences M&A Year in Review blog post , decreased valuations and challenging capital markets also impacted healthcare companies last year, and digital health companies – health companies that build and sell technology – were no exception.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52